533 results about "Pulmonary hypertension" patented technology

Interatrial shunts are described herein that are designed to benefit both the left side of the heart and the right side of the heart. The interatrial shunt is anchored in the atrial septum to permit blood to flow between atrial heart chambers across the atrial septum. In accordance with some aspects, the lumen of the shunt has an effective orifice area selected to permit blood flow across the atrial septum to unload the patient's left ventricle with beneficial effects on the patient's right ventricle. The shunts are structured to be suitably anchored at the atrial septum for long-term implantation. Further, the shunts preferably have insignificant late lumen loss. The interatrial shunts are expected to treat pathologies such as heart failure and pulmonary hypertension.

To provide a device that can be used to treat pulmonary hypertension with pulmonary denervation.SOLUTION: A multi-pole synchronous pulmonary artery radiofrequency ablation catheter is provided. An adjustment apparatus is arranged on a control handle 2. A cavity is arranged in a catheter body 1. A lead wire, a temperature sensing wire and a pull wire are arranged in the cavity. One end of the catheter body is flexible and connected to an annular ring 4. Tension of the pull wire is adjusted through the adjustment apparatus to achieve radian control of the flexible end. A shape memory wire is arranged in the annular ring, and has one end extending to a tip of the annular ring, and the other end passing through a root of the annular ring and fixed on the flexible end of the catheter body. The annular ring is provided with an electrode group with each electrode 5 connected to the lead wire and temperature sensing wire. The lead wire and the temperature sensing wire go through the catheter body and are electrically connected to the control handle.SELECTED DRAWING: Figure 1

The invention relates to substituted pyrazolo piperidine carboxylic acids, their salts and to processes for their preparation, and also to their use for preparing medicaments for the treatment and / or prophylaxis of diseases, in particular cardiovascular and cardiac diseases, preferably heart failure with reduced and preserved ejection fraction (HFrEF, HFmrEF and HFpEF), hypertension (HTN), peripheral arterial diseases (PAD, PAOD), cardio-renal and kidney diseases, preferably chronic and diabetic kidney disease (CKD and DKD), cardiopulmonary and lung diseases, preferable pulmonary hypertension (PH), and other diseases, preferably neurodegenerative diseases and different forms of dementias, fibrotic diseases, systemic sclerosis (SSc), sickle cell disease (SCD), wound healing disorders such as diabetic foot ulcer (DFU).

To provide formulations for treatment of hypertension, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pains, asthma, pulmonary arterial hypertension, and chronic obstructive pulmonary disease.SOLUTION: The invention provides a chemical formulation for use in a method of treating a disease, the method comprising: inserting a delivery catheter into a vascular lumen adjacent to nerves, where the vascular lumen includes a pulmonary artery; infusing the chemical formulation into the vascular lumen through the delivery catheter, where the amount of the chemical formulation is an amount effective to injure or damage the nerves and provide benefits in alleviating the symptoms of the disease; and withdrawing the delivery catheter from the blood vessel. The chemical formulation is at least one of 10-100 wt.% of ethanol, and 1-100 wt.% of acetic acid. The disease includes pulmonary arterial hypertension.SELECTED DRAWING: None

The present disclosure is directed to pharmaceutical compositions comprising a PDE V inhibitor and one or more pharmaceutical excipients or additives wherein the pharmaceutical compositions are in the form of liquid pharmaceutical compositions. The pharmaceutical compositions of the present disclosure are useful for the treatment of diseases or conditions which are treatable by administration of PDE V inhibitor drug such as pulmonary arterial hypertension, erectile dysfunction, etc.

Embodiments of the present invention are directed to the treatment of hypertension, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pains, asthma, pulmonary arterial hypertension, and chronic obstructive pulmonary disease by delivering of an effective amount of formulations at desired temperature to target tissue. The formulations include gases, vapors, liquids, solutions, emulsions and suspensions of one or more ingredients. The temperature may enhance safety and efficacy of the formulations for the treatments. The amounts of the formulation and / or energy are effective to injury or damage the tissues to have a benefit of symptom relive.

The invention features polypeptides that include an extracellular ActRIIA variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRIIA variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving low red blood cell levels, e.g., anemia or blood loss; fibrosis; or pulmonary hypertension.

Interatrial shunts having incorporated physiologic sensors are provided for monitoring and treating cardiovascular syndromes, including heart failure and pulmonary hypertension, in which the one or more sensors are affixed to the shunt to measure a physiologic parameter within the interatrial shunt. The one or more sensors may be directly affixed to or within a lumenal surface of the shunt or may be disposed on a support structure in a spaced relation to the shunt lumen, the one or more sensors disposed at locations subject to little or no pannus formation or cardiac wall motion artifact.

The invention features polypeptides that include an extracellular ActRIIB variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRIIB variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving weakness and atrophy of muscles, bone damage, low red blood cell levels (e.g., anemia or blood loss), fibrosis, and / or pulmonary hypertension.

The exemplified methods and systems facilitate the quantification of cardiac cycle-variability as a metric of signal quality of an acquired signal data set and the rejection, based on that quantification, of said acquired signal data set from one or more subsequent analyses that can predict and / or estimate a metric associated with the presence, non-presence, severity, and / or localization of abnormal cardiovascular conditions or disease, including, for example, but not limited to, coronary artery disease, abnormal left ventricular end-diastolic pressure disease (LVEDP), pulmonary hypertension and subcategories thereof, heart failure (HF), among others as discussed herein. The quantification of levels of cycle-variability assessed noise such as skeletal-muscle-related-signal contamination and muscle-artifact-noise contamination, and other asynchronous-noise contamination in an acquired signal can be subsequently used for the automated rejection of such asynchronous noise from measurements of biophysical signals.

A clinical decision support system and method for patients with pulmonary arterial hypertension is disclosed herein. The system may comprise a processor to process instructions to execute one or more pulmonary arterial hypertension risk algorithms configured to generate a risk score value associated with a patient surviving within a given time period. The system may comprise a means for input and output, wherein input variable data may be received and a set of risk score values may be displayed. A method for operating the clinical decision support system is also disclosed.

There are provided polypeptides that include an Activin receptor type IIB (ActRIIB) ectodomain (ECD) variant. In some embodiments, a polypeptide of the disclosure includes an ActRIIB-ECD variant fused to an Fc domain moiety. The disclosure also provides pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions associated with TGFβ superfamily ligand signaling, such as metabolic disorders, diabetes, obesity, cardiometabolic disease, pulmonary hypertension, fibrosis, muscle weakness and atrophy, bone damage, and / or low red blood cell levels (such as anemia).

There are provided polypeptides that include an Activin receptor type IIB (ActRIIB) ectodomain (ECD) variant. In some embodiments, a polypeptide of the disclosure includes an ActRIIB-ECD variant fused to an Fc domain moiety. The disclosure also provides pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions associated with TGFβ superfamily ligand signaling, such as pulmonary hypertension, fibrosis, muscle weakness and atrophy, metabolic disorders and / or cardiometabolic disease, bone damage, and / or low red blood cell levels (such as anemia).

The invention relates to substituted pyrazolo piperidine carboxylic acids, their salts and to processes for their preparation, and also to their use for preparing medicaments for the treatment and / or prophylaxis of diseases, in particular cardiovascular and cardiac diseases, preferably heart failure with reduced and preserved ejection fraction (HFrEF, HFmrEF and HFpEF), hypertension (HTN), peripheral arterial diseases (PAD, PAOD), cardio-renal and kidney diseases, preferably chronic and diabetic kidney disease (CKD and DKD), cardiopulmonary and lung diseases, preferable pulmonary hypertension (PH), and other diseases, preferably neurodegenerative diseases and different forms of dementias, fibrotic diseases, systemic sclerosis (SSc), sickle cell disease (SCD), wound healing disorders such as diabetic foot ulcer (DFU).

Systems and methods and devices are provided for treating conditions such as heart failure and / or pulmonary hypertension by at least partially occluding flow through the superior vena cava for an interval spanning multiple cardiac cycles. A catheter with an occlusion device is provided along with a controller that actuates a drive mechanism to provide at least partial occlusion of the patient's superior vena cava, which reduces cardiac filling pressures, and induces a favorable shift in the patient's Frank-Starling curve towards healthy heart functionality and improved cardiac performance. The occlusion device may include a lumen obstructed by a relief valve that may permit fluid flow through the occlusion device to release an excessive build-up of pressure.

The illustrative methods and systems facilitate one or more dynamic analyses that can characterize and identify synchronization between acquired cardiac signals and photoplethysmography signals to predict / estimate the presence, location, and / or severity of abnormal cardiovascular conditions or diseases, including, for example, but not limited to, coronary artery disease, heart failure (including but not limited to indicators of disease or condition, such as abnormal left ventricular end-diastolic pressure disease), and pulmonary hypertension. In some embodiments, statistical properties of the synchronization between the cardiac signal and the photoplethysmography signal are evaluated. In some embodiments, statistical properties of a histogram of synchronization between the cardiac signal and the photoplethysmography signal are evaluated. In some embodiments, statistical and / or geometric properties of a Poincare map of synchronization between the cardiac signal and the photoplethysmography signal are evaluated.

The invention provides a pulmonary arterial hypertension lesion artificial intelligence prediction method and device. The pulmonary artery high pressure lesion artificial intelligence prediction method based on pulmonary artery CTA imaging comprises the following steps: 1, acquiring a pulmonary artery CTA image of a patient; 2, segmenting the pulmonary artery CTA image of the patient by using a convolutional neural network to obtain a multi-substructure segmentation result; 3, obtaining morphological parameters according to a structure segmentation result; 4, constructing a dichotomy model by utilizing machine learning according to the obtained morphological parameters; and 5, predicting whether the patient suffers from pulmonary arterial hypertension or not by using the dichotomy model.

The utility model relates to the technical field of medical instruments, in particular to a pulmonary artery wedge pressure balloon. The pulmonary artery wedge pressure balloon comprises a catheter and a balloon body, one end of the catheter is provided with an inclined and elastic bent section, the balloon body is arranged on the outer wall of the end of the bent section, an airflow cavity channel communicated with an inner cavity of the balloon body is formed in the catheter, and the airflow cavity channel penetrates out of the side wall of the other end of the catheter. The pulmonary artery pressure detector has the advantages that the structural design is simple and reasonable, the use cost is low, and the pulmonary vessel pressure information of a pulmonary artery hypertension patient can be effectively detected, so that medical staff can judge the drug effect of administration according to the information or accurately evaluate the interventional operation of the patient.

Disclosed herein are kits and methods for treating pulmonary arterial hypertension (PAH), the method comprising administering to a subject in need thereof: * a therapeutically effective amount of a tyrosine kinase inhibitor or a pharmaceutically acceptable salt thereof; and * a therapeutically effective amount of a dimeric fusion protein comprising: * an extracellular domain of activin type 2A (ACTR IIA) or activin type 2B receptor (ACTR IIB); and an Fc domain of human immunoglobulin G1 (IgG1). In some embodiments, the tyrosine kinase inhibitor is cellatinib or a pharmaceutically acceptable salt thereof, and the fusion protein is sotasercept.

The invention discloses an application of beta-alanine in preparation of a medicine for treating pulmonary arterial hypertension. In-vivo and in-vitro pharmacological experiments prove that beta-alanine can inhibit lactic acid-mediated histone milk acylation modification and hypoxia-induced phenotypic transformation of PASMCs (Polyaspartic Sulfonate Molecules); the hemodynamics and pulmonary artery vascular remodeling of the PAH mouse are improved. The beta-alanine can inhibit phenotypic transformation of PASMCs and reverse pulmonary artery vascular remodeling which is a key pathological change in the pulmonary hypertension generation process, has huge potential in treatment of pulmonary hypertension, and has good application prospects and high clinical application value.

The invention discloses a construction method and application of a hypercongenital heart disease-pulmonary arterial hypertension model, which better simulates children with the congenital heart disease in Yunnan by adopting the conditions of lateral anastomosis of aorta abdominalis and inferior vena cava and hypoxia feeding, and makes a new contribution to the research of pulmonary arterial hypertension. In the experimental shunt + hypoxia group and the monocrotaline + hypoxia group, the heart of the SD rat has the change of pulmonary arterial hypertension, four cases in the shunt + hypoxia group have tricuspid regurgitation, and the rest experimental rats have no tricuspid regurgitation.

This document discloses a computer-implemented method for non-invasive assessment of pulmonary arterial hypertension PH from heart sound signals, the method comprising the steps of: receiving sound signals acquired from a beating heart of a subject for a predetermined period of time; generating one or more 2D feature maps, the feature maps including a 2D feature map having the received sound signals, where a first axis of the map is arranged in time and a second axis of the map is arranged on each heartbeat; a pre-trained neural network is applied to associate the generated one or more 2D feature maps with a previously acquired training dataset and to generate training 2D feature maps for a set of PH subjects and a set of non-PH subjects, thus obtaining an indication of the presence of pulmonary arterial hypertension. The invention also discloses a training method and system of the neural network.

The invention features polypeptides that include an extracellular ActRIIA variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRIIA variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving low red blood cell levels, e.g., anemia or blood loss; fibrosis; or pulmonary hypertension.

The invention relates to substituted pyrazolo piperidine carboxylic acids, their salts and to processes for their preparation, and also to their use for preparing medicaments for the treatment and / or prophylaxis of diseases, in particular cardiovascular and cardiac diseases, preferably heart failure with reduced and preserved ejection fraction (HFrEF, HFmrEF and HFpEF), hypertension (HTN), peripheral arterial diseases (PAD, PAOD), cardio-renal and kidney diseases, preferably chronic and diabetic kidney disease (CKD and DKD), cardiopulmonary and lung diseases, preferable pulmonary hypertension (PH), and other diseases, preferably neurodegenerative diseases and different forms of dementias, fibrotic diseases, systemic sclerosis (SSc), sickle cell disease (SCD), wound healing disorders such as diabetic foot ulcer (DFU).

The inhalation suspension preparation containing the SGC receptor stimulant comprises the SGC receptor stimulant with an effective therapeutic dose or pharmaceutically acceptable salt of the SGC receptor stimulant, and pharmaceutically acceptable auxiliary materials of the suspension preparation, the pharmaceutically acceptable auxiliary materials of the suspension preparation comprise at least one of a surfactant, a pH regulator, an osmotic pressure regulator and a metal complexing agent; the inhalation suspension preparation containing the riociguat shows good lung absorption efficiency, is beneficial to reaching the same or better treatment level by reducing the administration dosage, can directly act on a diseased region through an administration route, takes effect more quickly compared with oral administration of the riociguat, and has a good application prospect. Gastrointestinal discomfort and systemic hypotension side effects caused by gastrointestinal tract contact and absorption entering a circulatory system can be avoided, the treatment cycle of an oral dosage form dosage titration administration scheme is shortened, and a better treatment scheme is provided for relieving dyspnea and syncope symptoms of pulmonary hypertension patients treated at home.

The invention provides application of edaravone and pharmaceutically acceptable salts thereof in prevention and / or treatment of acute high altitude diseases caused by acute plateau hypobaric hypoxia. The acute high altitude diseases include, for example, acute altitude stress (AMS), plateau acute brain injury (HACE), and plateau acute lung injury (HAPE). In addition, the present disclosure provides the use of edaravone and pharmaceutically acceptable salts thereof for the prevention and / or treatment of inflammatory responses caused by plateau pulmonary arterial hypertension (HAPH) and acute plateau hypobaric hypoxia.

The present application provides a recombinant fusion protein comprising a human activin receptor 2A extracellular domain optionally fused to an immunoglobulin heavy chain constant region via a linker wherein the human ACVR2A extracellular domain comprises a mutation from Asn (N) to Ala (A) at a site corresponding to position 24 of the sequence as shown in SEQ ID NO: 1 to remove glycosylation sites.

Systems and methods are disclosed to an ambulatory medical device. The ambulatory medical device comprising an activity sensor configured to produce an activity signal representative of activity level of a patient, a heart sound sensor configured to produce a heart sound signal, and a control circuit. The control circuit is configured to detect a change in activity level of the patient using the activity signal, enable monitoring of the heart sound signal in response to detecting the change in activity level, measure intensity of an S3 heart sound in the heart sound signal, and produce an indication of pulmonary hypertension (PH) when the measured intensity of the S3 heart sound exceeds a PH detection threshold intensity.

The invention discloses an application of 4-octyl itaconic acid (4-OI) in preparation of a medicine for improving pulmonary arterial hypertension (PAH). In-vivo experiments show that 4-OI can significantly reduce pulmonary vascular wall thickening and collagen deposition of a PAH rat model, and effectively improve PAH and vascular remodeling. In-vitro experiments further reveal that 4-OI reduces endoplasmic reticulum stress (ERS) by inhibiting a PERK-eIF2alpha pathway, further blocks SM22 dependent smooth muscle cell phenotypic transformation and endothelial-mesenchymal transformation (EndMT) processes, finally inhibits vascular remodeling, and plays a role in treating PAH. The three key pathological processes of ERS, EndMT and vascular remodeling are closely linked, a new perspective is provided for deeply understanding the correlation among oxidative stress, endothelial dysfunction and vascular structure change in PAH, meanwhile, a theoretical foundation is laid for developing PAH and vascular remodeling accurate treatment drugs, and clinical transformation value is achieved.

The invention features methods of treating a disease or condition associated with elevated activin signaling (e.g., a bone disease, pulmonary hypertension, fibrosis, a muscle disease, a metabolic disease, thrombocytopenia, or neutropenia) by administering to a human subject a polypeptide including an extracellular ActRIIB variant fused to an Fc domain in an amount of 1.5 mg / kg to 4.5 mg / kg at a frequency of once every 28 days.